BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 6972728)

  • 1. Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli.
    Verbist L
    Antimicrob Agents Chemother; 1981 Mar; 19(3):407-13. PubMed ID: 6972728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefoxitin sensitivity as a marker for inducible beta-lactamases.
    Moritz VA; Carson PB
    J Med Microbiol; 1986 May; 21(3):203-7. PubMed ID: 3486293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains].
    Mascellino MT; Prignano G; Iegri F; Lorenzi A
    Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the beta-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa.
    Livermore DM; Williams RJ; Williams JD
    J Antimicrob Chemother; 1981 Oct; 8(4):323-31. PubMed ID: 6271726
    [No Abstract]   [Full Text] [Related]  

  • 6. GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.
    Verbist L; Verhaegen J
    Antimicrob Agents Chemother; 1980 May; 17(5):807-12. PubMed ID: 6994640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of ceftazidime and other cephalosporins to a range of beta-lactamases and their potential as inducing agents.
    Mouton RP; Bongaerts GP; van Gestel MH
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():147-52. PubMed ID: 19802978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin.
    Fu KP; Neu HC
    Antimicrob Agents Chemother; 1980 Apr; 17(4):583-90. PubMed ID: 6967294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activity of new beta-lactam antibiotics].
    Cullmann W; Stieglitz M
    Fortschr Med; 1982 May; 100(19):888-92. PubMed ID: 6807788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and specific beta-lactamase susceptibility of cefoperazone and moxalactam. Comparison with other cephalosporins.
    Mouton RP; Bongaerts GP; van Gestel M; Bruggeman-Ogle KM
    Chemotherapy; 1981; 27(5):318-24. PubMed ID: 6455258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activity of first, second and third generation cephalosporins.
    Forsgren A
    Acta Pathol Microbiol Scand B; 1981 Aug; 89(4):221-5. PubMed ID: 6274143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases.
    Livermore DM; Williams RJ; Williams JD
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():163-7. PubMed ID: 19802980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and azthreonam.
    Appelbaum PC; Tamim J; Pankuch GA; Aber RC
    Chemotherapy; 1983; 29(5):337-44. PubMed ID: 6311492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 Jun; 17(6):937-42. PubMed ID: 6250470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
    Adamsson L; Dornbusch K; Hallander HO
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.
    Fuchs PC; Jones RN; Barry AL; Thornsberry C
    Antimicrob Agents Chemother; 1985 May; 27(5):679-82. PubMed ID: 3893316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.
    Kurtz TO; Winston DJ; Hindler JA; Young LS; Hewitt WL; Martin WJ
    Antimicrob Agents Chemother; 1980 Oct; 18(4):645-8. PubMed ID: 6255864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of in vitro activities of eight new beta-lactam compounds against cephalothin-resistant Enterobacteriaceae from hospital patients.
    Costopoulos C; Legakis NJ; Papafragas E; Marinis E
    Chemotherapy; 1984; 30(3):158-64. PubMed ID: 6610538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.